Targeting constitutively active <scp>STAT3</scp> in chronic lymphocytic leukemia: A clinical trial of the <scp>STAT3</scp> inhibitor pyrimethamine with pharmacodynamic analyses
Jennifer R. Brown(Dana-Farber Cancer Institute), David A. Frank(Brigham and Women's Hospital), Stacey M. Fernandes(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University), Erik A. Nelson(Brigham and Women's Hospital), Michael Xiang(University of California, Los Angeles), Jennifer Yeh(Stanford University), Arnold S. Freedman(Otsuka (Japan)), Catherine J. Wu(Dana-Farber Cancer Institute), Maria Nicolais(Dana-Farber Cancer Institute), M. Chaudhury(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Josephine L. Klitgaard(Dana-Farber Cancer Institute), Sarah R. Walker(Harvard University Press), Eric D. Jacobsen(Dana-Farber Cancer Institute), Zachary T. Giaccone(Dana-Farber Cancer Institute), Jeffrey G. Supko(Harvard University), Yasmin Kroll(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Lisa N. Heppler(Dana-Farber Cancer Institute)
Cited by 29
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Towards personalized, tumour-specific, therapeutic vaccines for cancer
|Nature reviews. Immunology|2017|1k